(N)-methanocarba 2,N6-disubstituted adenine nucleosides as highly potent and selective A3 adenosine receptor agonists

Journal of Medicinal Chemistry

Volumn 48, Issue 6, 2005, Pages 1745-1758

  Tchilibon, Susanna ^a   Joshi, Bhalchandra V ^a   Kim, Soo Kyung ^a   Duong, Heng T ^a   Gao, Zhan Guo ^a   Jacobson, Kenneth A ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE A3 RECEPTOR AGONIST; ADENYLATE CYCLASE; BENZYLAMINE DERIVATIVE; ESTER; FORSKOLIN; RIBOSE;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CELL VIABILITY; CHEMICAL STRUCTURE; DRUG SELECTIVITY; ENZYME INHIBITION; MITSUNOBU REACTION; MOLECULAR MODEL; NONHUMAN; POLYMERIZATION; RAT; STRUCTURE ACTIVITY RELATION;

ADENINE; ANIMALS; BINDING SITES; CHO CELLS; CRICETINAE; CRICETULUS; CYCLIC AMP; HUMANS; MODELS, MOLECULAR; NUCLEOSIDES; RADIOLIGAND ASSAY; RATS; RECEPTOR, ADENOSINE A3; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 15444378502     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm049580r     Document Type: Article

References (64)

1. Fredholm, B. B.; IJzerman, A. P.; Jacobson, K. A.; Klotz, K.-N.; Linden, J. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol. Rev. 2001, 53, 527-552.
2. Yao, L.; Burbiel, J. C.; Maass, A.; Müller, C. E. Adenosine receptor agonists: from basic medicinal chemistry to clinical development. Expert Opin. Emerging Drugs 2003, 8, 537-576.
3. Ohta, A.; Sitkovsky, M. Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature 2001, 414, 916-920.
4. 3 receptor: sustained cardioprotection, Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 6995-6999.
5. 3 receptor stimulation and cerebral ischemia. Eur. J. Pharmacol. 1994, 263, 59-67.
6. 2B receptor. J. Med. Chem. 2001, 44, 170-179.
7. 1-adenosine receptor selectively slows AV conduction in guinea pig hearts. Am. J. Physiol.: Heart Circ. Physiol. 2001, 280, H334-H343.
8. 3 adenosine receptor: Sensitivity to hypoxic neurodegeneration. Cell. Mol. Neurobiol. 2003, 23, 431-447.
9. 2A adenosine receptor activation improves survival in mouse models of endotoxemia and sepsis. J. Infect. Dis. 2004, 189, 1897-1904.
10. 3 adenosine receptor agonist CF101. Br. J. Cancer 2003, 89, 1552-1558.
11. Avila, M. Y.; Stone, R. A.; Civan, M. M. Invest. Ophthalmol. Visual Sci. 2002, 43, 3021-3026.
12. 3 adenosine receptor activation: Nucleoside ligands at the agonist/antagonist boundary. J. Med. Chem. 2002, 45, 4471-4484.
13. 3-selective adenosine agonists. J. Med. Chem. 1994, 37, 636-646.
14. 3-adenosine receptors. J. Med. Chem. 1994, 37, 3614-3621.
15. Tracey, W. R.; Magee, W. P.; Oleynek, J. J.; Hill, R. J.; Smith, A. H.; Flynn, D. M.; Knight, D. R. Am. J. Physiol.: Heart Circ. Physiol. 2003, 285, H2780.
16. 1 adenosine receptor. Basic Res. Cardiol. 2001, 96, 487-496.
17. 3 adenosine receptors. Biochem. Pharmacol. 2003, 65, 1675-1684.
18. Ohno, M.; Gao, Z. G.; Van Rompaey, P.; Tchilibon, S.; Kim, S. K.; Harris, B. A.; Blaustein, J.; Gross, A. S.; Duong, H. T.; Van Calenbergh, S.; Jacobson, K. A. Modulation of adenosine receptor affinity and intrinsic efficacy in nucleosides substituted at the 2-position. Bioorg. Med. Chem. 2004, 12, 2995-3007.
19. Hannon, J. P.; Bray-French, K. M.; Phillips, R. M.; Fozard, J. R. Further pharmacological characterization of the adenosine receptor subtype mediating inhibition of oxidative burst in human isolated neutrophils. Drug Dev. Res. 1998, 43, 214-224.
20. Jacobson, K. A.; Ji, X.-d.; Li, A.-H.; Melman, N.; Siddiqui, M. A.; Shin, K.-J.; Marquez, V. E.; Ravi, R. G. Methanocarba analogues of purine nucleosides as potent and selective adenosine receptor agonists. J. Med. Chem. 2000, 43, 2196-2203.
21. 3 adenosine receptor agonists. Presented at the 227th National Meeting of the American Chemical Society, Boston, MA, August 2002; Paper MEDI 256.
22. 3 adenosine receptor agonists. J. Org. Chem., in press.
23. Lee, K.; Ravi, R. G.; Ji, X.-d.; Marquez, V. E.; Jacobson, K. A. Ring-constrained (N)methanocarba-nucleosides as adenosine receptor agonists: Independent 5′-uronamide and 2′-deoxy modifications, Bioorg. Med. Chem. Lett. 2001, 11, 1333-1337.
24. 6-(2-phenylethyl)adenosine derivatives as potent ligands. Bioorg. Med. Chem. 2004, 12, 2021-2034.
25. Klotz, K.-N.; Hessling, J.; Hegler, J.; Owman, C.; Kull, B.; Fredholm, B. B.; Lohse, M. J. Comparative pharmacology of human adenosine receptor subtypes - characterization of stably transfected receptors in CHO cells. Naunyn-Schmiedeberg's Arch. Pharmacol. 1998, 357, 1-9.
26. Palczewski, K.; Kumasaka, T.; Hori, T.; Behnke, C. A.; Motoshima, H.; Fox, B. A.; Le Trong, I.; Teller, D. C.; Okada, T.; Stenkamp, T. E.; Yamamoto, M.; Miyano, M. Crystal structure of rhodopsin: A G protein-coupled receptor. Science 2000, 289, 739-745.
27. 3 adenosine receptor. Mol. Pharmacol. 2003, 63, 1021-1031.
28. Mitsunobu, O. The use of diethyl azodicarboxylate and triphenylphosphine in synthesis and transformation of natural products. Synthesis 1981, 1, 1-28.
29. Wilson, A. A.; Dannals, R. F.; Ravert, H. T.; Frost, J. J.; Wagner, H. N., Jr. Potent muscarinic cholinergic receptor antagonist. J. Med. Chem. 1989, 32, 1057-1062.
30. Treu, M.; Frohlich, J.; Jordis, U. Preparation of shortened norbelladine analogs. Molecules 2002, 7, 743-750.
31. Williams, R. M.; Ehrlich, P. P.; Zhai, W.; Hendrix, J. A new synthetic approach to 1-(hydroxymethyl)-8-methoxy-1,2,3,4-tetrahydroisoqyuinolin-4-one. J. Org. Chem. 1989, 52, 2615-2617.
32. Sonogashira, K.; Tohda, Y.; Hagihara, N. A convenient synthesis of acetylenes: catalytic substitutions of acetylenic hydrogen with bromoalkenes, iodoarenes and bromopyridines. Tetrahedron Lett. 1975, 4467-4470.
33. Tucker, T. J.; Brady, S. F.; Lumma, W. C.; Lewis, S. D.; Gardell, S. J.; Naylor-Olsen, A. M.; Yan, Y.; Sisko, J. T.; Stauffer, K. J.; Lucas, B. J.; Lynch, J. J.; Cook, J. J.; Stranieri, M. T.; Holahan, M. A.; Lyle, E. A.; Baskin, E. P.; Chen, I. W.; Dancheck, K. B.; Krueger, J. A.; Cooper, C. M.; Vacca, J. P. Design and synthesis of a series of potent and orally bioavailable noncovalent thrombin inhibitors that utilize nonbasic groups in the P1 position. J. Med. Chem. 1998, 41, 3210-3219.
34. Kim, H. S.; Ohno, M.; Xu, B.; Kim, H. O.; Choi, Y.; Ji, X. D.; Maddileti, S.; Marquez, V. E.; Harden, T. K.; Jacobson, K. A. 2-Substitution of adenine nucleotide analogues containing a bicyclo[3.1.0]hexane ring system locked in a Northern conformation: Enhanced potency as P2Y1 receptor antagonists. J. Med. Chem. 2003, 46, 4974-4987.
35. Brun, V.; Legraverend, M.; Grierson, D. S. Cyclin-dependent kinase (CDK) inhibitors: development of a general strategy for the construction of 2,6,9-trisubstituted purine libraries. Part 1. Tetrahedron Lett. 2001, 42, 8161-8164.
36. 3 adenosine receptor. Mol. Pharmacol. 1994, 45, 978-982.
37. 2B ligands. J. Med. Chem. 2002, 45, 3271.
38. 3 selective ligands containing bioisosteric isoxazoles. Bioorg. Med. Chem. Lett. 1998, 8, 1767-1770.
39. Wildbrandt, R.; Frotscher, U.; Freyland, M.; Messerschmidt, W.; Richter, R.; Schulte-Lippern, M.; Zschaege, B. Treatment of glomerulonephritis with metrifudil. Preliminary Report. Med. Klin. (Muenchen) 1972, 67, 1138-1140.
40. 3 adenosine and P2Y receptors and their ligands. Drug Dev. Res. 2003, 58, 330-339.
41. 3 adenosine receptors in human lymphocytes: Up-regulation in T cell activation. Mol. Pharmacol. 2004, 65, 711-719.
42. 3 adenosine receptor in monocyte-derived dendritic cells and recombinant cells. Mol. Pharmacol. 2003, 63, 342-350.
43. 3 receptor. J. Immunol. 2003, 171, 338-345.
44. 3 receptor- and mast cell-dependent and -independent components of adenosine-mediated airway responsiveness in mice. J. Immunol. 2003, 171, 331-337.
45. 3 adenosine receptors. Circ. Res. 2003, 92, 485-492.
46. 3 adenosine receptor agonist potentiates natural killer cell activity. Int. J. Oncol. 2003, 23, 1245-1249.
47. 3 adenosine and CB1 receptors activate a PKC-sensitive Cl- current in human nonpigmented ciliary epithelial cells via a Gβ,γ-coupled MAPK signaling pathway. Br. J. Pharmacol. 2003, 139, 475-486.
48. 3 adenosine receptor gene promoter in transgenic mice: characterization of previously unidentified sites of expression. FEBS Lett. 2002, 532, 267-272.
49. 3 receptor agonist: IB-MECA, on scopolamine-and MK-801-induced memory impairment. Behav. Brain Res. 2003, 141, 11-17.
50. 3 adenosine receptor agonists. J. Biol. Chem. 2000, 275, 30272-30279.
51. 3 receptor. J. Med. Chem. 2003, 46, 353.
52. 3) agonists as agents for perioperative cardioprotection. Presented at the 224th National Meeting of the American Chemical Society, Boston, MA, August 2002; Paper MEDI 291.
53. 3 receptor. J. Med. Chem. 1999, 42, 1393-1400.
54. de Zwart, M.; Link, R.; von Frijtag Drabbe Künzel, J. K.; Cristalli, G.; Jacobson, K. A.; Townsend-Nicholson, A.; IJzerman, A. P. A screening of adenosine analogues on the human adenosine A2B receptor as part of a search for potent and selective agonists. Nucleosides Nucleotides 1998, 17, 969-986.
55. Bradford, M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 72, 248-254.
56. Nordstedt, C.; Fredholm, B. B. A modification of a protein-binding method for rapid quantification of cAMP in cell-culture supernatants and body fluid. Anal. Biochem. 1990, 189, 231-234.
57. Post, S. R.; Ostrom, R. S.; Insel, P. A. Biochemical methods for detection and measurement of cyclic AMP and adenylyl cyclase activity. Methods Mol. Biol. 2000, 126, 363-374.
58. 50) of an enzymatic reaction. Biochem. Pharmacol. 1973, 22, 3099-3108.
59. Sybyl Molecular Modeling System, version 6.9; Tripos Inc. (1969 South Hanley Road, St. Louis, MO 63144).
60. Halgren, T. A. MMFF VII. Characterization of MMFF94, MMFF94s, and other widely available force fields for conformational energies and for intermolecular-interaction energies and geometries. J. Comput. Chem. 1999, 20, 730-748.
61. Cornell, W. D.; Cieplak, P.; Bayly, C. I.; Gould, I. R.; Merz, K. M., Jr.; Ferguson, D. M.; Spellmeyer, D. C.; Fox, T.; Caldwell, J. W.; Kollman, P. A. A second generation force field for the simulation of proteins, nucleic acids and organic molecules. J. Am. Chem. Soc. 1995, 117, 5179-5197.
62. Residues that were within 5 Å of the ligand in this putative binding site were the following: L91 (3.33), T94 (3.36), H95 (3.37), N150 (EL2), Q167 (EL2), F168 (EL2), S181 (5.42), M177 (5.38), V178 (5.39), F182 (5.43), W243 (6.48), L246 (6.51), S247 (6.52), N250 (6.55), 1268 (7.39), S271 (7.42), and H272 (7.43).
63. 6-benzyl binding region resulted in weak H-bonding interactions at the hydroxyl and 5′-uronamide groups of methanocarba ring, thus decreasing the binding affinity.
64. 6-benzyl ring, and its hydroxyl group entered a hydrophilic region.